Overview
Reunion Neuroscience is developing RE104, a novel psychedelic compound with a shorter duration of action than psilocybin, targeting postpartum depression and major depressive disorder. Their approach aims to improve practicality of psychedelic-assisted therapy.
More in Mental Health Tech
Latest industry news
Generative AI Is Closing the Gap on Brain-Computer Interface Accuracy and Resolution
2026-11-11 ยท Research
Spiking Neural Networks Emerge as a Viable Shield Against Signal Noise in Brain-Computer Interfaces
2026-11-10 ยท Research
China's Brain-Reading Device Hits 94% Mind-Typing Accuracy Over a Full Day of Use
2026-11-09 ยท Research
Wearable Brain-Computer Interfaces Are Closer to Mainstream Than You Think
2026-11-08 ยท Industry
Company details
Category
๐ Mental Health Tech
Location
Montreal, Canada
Funding
Public ยท NASDAQ: REUN
Website
reunionneuroscience.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ